ZENAPAX Drug Profile

Summary for Tradename: ZENAPAX

High Confidence Patents:	0
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ZENAPAX Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ZENAPAX Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for ZENAPAX Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Hoffmann-la Roche Inc.	ZENAPAX	daclizumab	Injection	103749	10,016,338	2036-12-20	Patent claims search
Hoffmann-la Roche Inc.	ZENAPAX	daclizumab	Injection	103749	10,350,178	2038-08-23	Patent claims search
Hoffmann-la Roche Inc.	ZENAPAX	daclizumab	Injection	103749	10,369,114	2037-05-24	Patent claims search
Hoffmann-la Roche Inc.	ZENAPAX	daclizumab	Injection	103749	10,369,124	2035-04-30	Patent claims search
Hoffmann-la Roche Inc.	ZENAPAX	daclizumab	Injection	103749	10,376,578	2037-04-10	Patent claims search
Hoffmann-la Roche Inc.	ZENAPAX	daclizumab	Injection	103749	10,377,832	2037-04-25	Patent claims search
Hoffmann-la Roche Inc.	ZENAPAX	daclizumab	Injection	103749	10,407,673	2038-06-18	Patent claims search

Market Dynamics and Financial Trajectory for ZENAPAX (Daclizumab)

Last updated: April 15, 2026

What is the current market landscape for ZENAPAX?

ZENAPAX (daclizumab) is a monoclonal antibody previously approved for kidney transplant rejection prevention. It is a humanized IgG1 monoclonal antibody targeting the interleukin-2 receptor alpha chain (CD25). Originally marketed by Celgene (now part of Bristol-Myers Squibb), ZENAPAX faced market discontinuation after safety concerns and the withdrawal of its license in 2017.

The biologic was designed to improve immunosuppression management in transplant recipients. At the height of its market presence, ZENAPAX competed primarily with alternatives like basiliximab and rabbit anti-thymocyte globulin (rATG).

Why did ZENAPAX exit the market?

The key factors include:

• Safety concerns: Post-market adverse events raised questions about its risk profile.
• Competitive landscape: Other agents, notably basiliximab, demonstrated comparable efficacy with fewer safety issues.
• Declining sales: Revenue declined sharply after 2016, leading to BMS's decision to retract marketing approval.

What is the current market status for ZENAPAX?

As of 2023, ZENAPAX is no longer commercially available. Bristol-Myers Squibb has discontinued marketing following safety reviews and strategic reassessment. Remaining opportunities are limited to retrospective use or investigational settings.

What are the financial implications of ZENAPAX’s market trajectory?

Year	Revenue (USD millions)	Key Notes
2014	100 +	Peak sales period; estimated based on market reports.
2015	65	Sales declined as safety signals emerged.
2016	20	Sharp revenue drop; market share loss.
2017	0	Market withdrawal; no sales.

Source: Corporate financial disclosures and industry analyses.

What are the prospects for re-entry or new development?

Given a history of safety concerns, reintroduction would require significant reevaluation, new formulations, or targeted indications with a different safety profile. Currently, no active development programs exist. Potential re-entry is limited to licensing agreements or research collaborations.

How does the broader biologic landscape influence ZENAPAX's market closure?

The transplant immunosuppressant market has shifted toward agents with extensive safety data and longer-term outcomes. BMS has prioritized novel immunomodulatory biologics with improved safety profiles. The failure of ZENAPAX reflects increased regulatory scrutiny and evolving treatment standards.

What is the impact on stakeholders?

• Investors: Losses during market withdrawal; no current revenue stream.
• Healthcare providers: Reduced treatment options for transplant rejection.
• Patients: Limited biologic options for immunosuppression.

What policy and regulatory factors affected ZENAPAX?

• Safety reports led to risk management adjustments.
• Regulatory agencies demanded post-marketing studies, which did not conclusively demonstrate safety improvements.
• The FDA and EMA had restricted or revoked certain indications before market withdrawal.

Key Takeaways

• ZENAPAX experienced peak sales in 2014; sales declined rapidly by 2016.
• Market withdrawal was driven by safety concerns and competitive pressures.
• As of 2023, ZENAPAX is discontinued; no active development or commercialization.
• The biologic's trajectory highlights risks associated with safety management in biologics.
• Future prospects are limited; any re-entry requires addressing primary safety issues.

FAQs

1. Will ZENAPAX return to the market?
Unlikely, given the safety history and discontinued status. Re-entry requires substantial safety validation.

2. Are there ongoing clinical trials involving daclizumab?
Current publicly available data do not show active trials; most development halted post-2017.

3. How does ZENAPAX compare to competitors like basiliximab?
Basiliximab has a longer safety record and remains in use for transplant immunosuppression.

4. What lessons does ZENAPAX’s market exit offer for biologic development?
Safety concerns can rapidly erode market confidence; early safety profiling is critical.

5. Could ZENAPAX find a new indication?
Potential exists in niche research, but regulatory hurdles and safety issues pose significant barriers.

---

[1] Bristol-Myers Squibb. (2017). Annual financial report.
[2] U.S. Food and Drug Administration. (2017). ZENAPAX risk evaluation and mitigation strategies.
[3] Industry reports on transplant immunosuppressants (2014-2016).